M
Morris Robert Edward
Researcher at University of Edinburgh
Publications - 6
Citations - 1607
Morris Robert Edward is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Ruthenium & Biological activity. The author has an hindex of 5, co-authored 6 publications receiving 1521 citations. Previous affiliations of Morris Robert Edward include Western General Hospital.
Papers
More filters
Journal ArticleDOI
Inhibition of cancer cell growth by ruthenium(II) arene complexes
Morris Robert Edward,Rhona E. Aird,Piedad del Socorro Murdoch,Haimei Chen,Jeffrey Cummings,Nathan D. Hughes,Simon Parsons,Andrew Parkin,Gary Boyd,Duncan I. Jodrell,Peter J. Sadler +10 more
TL;DR: These chelated Ru(II) arene complexes have potential as novel metal-based anticancer agents with a mechanism of action different from that of the Ru(III) complex currently on clinical trial.
Journal ArticleDOI
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
R E Aird,Jeffrey Cummings,A.A. Ritchie,M. Muir,Morris Robert Edward,Haimei Chen,Peter J. Sadler,Duncan I. Jodrell +7 more
TL;DR: High activity coupled to non cross-resistance in cisplatin resistant models merit further development of this novel group of anticancer compounds.
Journal ArticleDOI
Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.
TL;DR: Investigation of nucleic acid derivatives by organometallic ruthenium(II) arene anticancer complexes has revealed that N7-binding is promoted by favorable arene-purine hydrophobic interactions in the associative transition state.
Patent
Half-sandwich ruthenium (ii) compounds comprising nitrogen containing ligands for treatment of cancer
TL;DR: In this paper, the authors defined the formula (I) for compounds which may be used in the treatment and/or prevention of cancer, where each compound is associated with one or more of the carbon atoms of the pyridine ring.
Patent
Ruthenium (ii) compounds for use in the therapy of cancer
TL;DR: In this paper, the authors define the formula (I): wherein R?1 and R2? together with the ring to which they are bound represent a saturated or unsaturated carbocyclic or heterocyclically group.